Target Health Inc. has announced the release of Target Document® version 1.5. Target Document® is a distributable, secure, user-friendly, 21 CFR Part 11 compliant, Internet-based, document sharing, distribution, and management system that allows users, depending on their roles and permissions, to post, share, electronically sign, and archive an electronic document within a Web browser. New features include advanced user management, access to recycle bin, parallel sign off of documents, manual backup of any folder, configuration of e-Signature text, document expiration dating, email alerts to all users, etc.
According to Jules Mitchel, MBA, Ph.D., President of Target Health, “Target Document® allows for a paperless Trial Master File (TMF) and is part of the paperless eClinical toolbox of products available from Target Health.”
The Target Health toolbox includes: Target e*CRF®, Target Health’s flagship EDC software, which has been used in clinical trials; Target Encoder® - which links into the Target e*CRF® database to encode MedDRA and WHODRUG terms; Target e*CTMS™ (Clinical Trial Management System)- which allows for Internet-based project management, across studies at one website ; and Target Newsletter® - which allows for a clinical trial newsletter with real time enrollment data and comments.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.